Search

Your search keyword '"Brugha, Rossa"' showing total 141 results
Start Over Author "Brugha, Rossa"
141 results on '"Brugha, Rossa"'

1. Levelling the playing field through the London Network of the UK clinical trials accelerator platform

Author

Matthews, Jessie, Dobra, Rebecca, Wilson, Gemma, Allen, Lucy, Bossley, Cara, Brendell, Rebecca, Brugha, Rossa, Brown, Danielle, Brown, Sarah, Cadiente, Shenna, Cameron, Loren, Davies, Gwyneth, Dawson, Charlotte, Elborn, Stuart, Hughes, Dominic, Longmate, Jess, Macedo, Patricia, Pappas, Leonidas, Pao, Caroline, Round, Chris, Ruiz, Gary, Saunders, Clare, Shafi, Nadia, Simmonds, Nicholas, Waller, Michael, Watson, Danie, and Davies, Jane C.

Published
2024
Full Text
View/download PDF

4. Favipiravir induces HuNoV viral mutagenesis and infectivity loss with clinical improvement in immunocompromised patients

Author

Kreins, Alexandra Y., Roux, Emma, Pang, Juanita, Cheng, Iek, Charles, Oscar, Roy, Sunando, Mohammed, Reem, Owens, Stephen, Lowe, David M., Brugha, Rossa, Williams, Rachel, Howley, Evey, Best, Timothy, Davies, E. Graham, Worth, Austen, Solas, Caroline, Standing, Joseph F., Goldstein, Richard A., Rocha-Pereira, Joana, and Breuer, Judith

Published
2024
Full Text
View/download PDF

14. Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study

Author

Mall, Marcus A., primary, Brugha, Rossa, additional, Gartner, Silvia, additional, Legg, Julian, additional, Moeller, Alexander, additional, Mondejar-Lopez, Pedro, additional, Prais, Dario, additional, Pressler, Tacjana, additional, Ratjen, Felix, additional, Reix, Philippe, additional, Robinson, Paul D., additional, Selvadurai, Hiran, additional, Stehling, Florian, additional, Ahluwalia, Neil, additional, Arteaga-Solis, Emilio, additional, Bruinsma, Bote G., additional, Jennings, Mark, additional, Moskowitz, Samuel M., additional, Noel, Sabrina, additional, Tian, Simon, additional, Weinstock, Tanya G., additional, Wu, Pan, additional, Wainwright, Claire E., additional, and Davies, Jane C., additional

Published
2022
Full Text
View/download PDF

19. Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation : A Phase 3b, Randomized, Placebo-controlled Study

Author

Mall, Marcus A, Brugha, Rossa, Gartner, Silvia, Legg, Julian, Moeller, Alexander, Mondejar-Lopez, Pedro, Prais, Dario, Pressler, Tacjana, Ratjen, Felix, Reix, Philippe, Robinson, Paul D, Selvadurai, Hiran, Stehling, Florian, Ahluwalia, Neil, Arteaga-Solis, Emilio, Bruinsma, Bote G, Jennings, Mark, Moskowitz, Samuel M, Noel, Sabrina, Tian, Simon, Weinstock, Tanya G, Wu, Pan, Wainwright, Claire E, Davies, Jane C, University of Zurich, and Wainwright, Claire E

Subjects
Pulmonary and Respiratory Medicine, 10036 Medical Clinic, 2740 Pulmonary and Respiratory Medicine, Medizin, 610 Medicine & health, 2706 Critical Care and Intensive Care Medicine, Critical Care and Intensive Care Medicine
Abstract

Rationale: The triple-combination regimen elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was shown to be safe and efficacious in children aged 6 through 11 years with cystic fibrosis and at least one F508del-CFTR allele in a phase 3, open-label, single-arm study. Objectives: To further evaluate the efficacy and safety of ELX/TEZ/IVA in children 6 through 11 years of age with cystic fibrosis heterozygous for F508del and a minimal function CFTR mutation (F/MF genotypes) in a randomized, double-blind, placebo-controlled phase 3b trial. Methods: Children were randomized to receive either ELX/TEZ/IVA (n = 60) or placebo (n = 61) during a 24-week treatment period. The dose of ELX/TEZ/IVA administered was based on weight at screening, with children,30 kg receiving ELX 100 mg once daily, TEZ 50 mg once daily, and IVA 75 mg every 12 hours, and children >30 kg receiving ELX 200 mg once daily, TEZ 100 mg once daily, and IVA 150 mg every 12 hours (adult dose). Measurements and Main Results: The primary endpoint was absolute change in lung clearance index₂.₅ from baseline through Week 24. Children given ELX/TEZ/IVA had a mean decrease in lung clearance index₂.₅ of 2.29 units (95% confidence interval [CI], 1.97–2.60) compared with 0.02 units (95% CI, 20.29 to 0.34) in children given placebo (between-group treatment difference, 22.26 units; 95% CI, 22.71 to 21.81; P, 0.0001). ELX/TEZ/IVA treatment also led to improvements in the secondary endpoint of sweat chloride concentration (between-group treatment difference, 251.2 mmol/L; 95% CI, 255.3 to 247.1) and in the other endpoints of percent predicted FEV₁ (between-group treatment difference, 11.0 percentage points; 95% CI, 6.9–15.1) and Cystic Fibrosis Questionnaire-Revised Respiratory domain score (between-group treatment difference, 5.5 points; 95% CI, 1.0–10.0) compared with placebo from baseline through Week 24. The most common adverse events in children receiving ELX/TEZ/IVA were headache and cough (30.0% and 23.3%, respectively); most adverse events were mild or moderate in severity. Conclusions: In this first randomized, controlled study of a cystic fibrosis transmembrane conductance regulator modulator conducted in children 6 through 11 years of age with F/MF genotypes, ELX/TEZ/IVA treatment led to significant improvements in lung function, as well as robust improvements in respiratory symptoms and cystic fibrosis transmembrane conductance regulator function. ELX/TEZ/IVA was generally safe and well tolerated in this pediatric population with no new safety findings.

Published
2022

20. Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study.

Author

Mall, Marcus A., Brugha, Rossa, Gartner, Silvia, Legg, Julian, Moeller, Alexander, Mondejar-Lopez, Pedro, Prais, Dario, Pressler, Tacjana, Ratjen, Felix, Reix, Philippe, Robinson, Paul D., Selvadurai, Hiran, Stehling, Florian, Ahluwalia, Neil, Arteaga-Solis, Emilio, Bruinsma, Bote G., Jennings, Mark, Moskowitz, Samuel M., Noel, Sabrina, and Tian, Simon

Subjects
LAXATIVES, RESEARCH, GENETIC mutation, PHENOLS, CLINICAL trials, HETEROCYCLIC compounds, RESEARCH methodology, EVALUATION research, CYSTIC fibrosis, COMPARATIVE studies, RANDOMIZED controlled trials, FORCED expiratory volume, MEMBRANE proteins
Abstract

Rationale: The triple-combination regimen elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was shown to be safe and efficacious in children aged 6 through 11 years with cystic fibrosis and at least one F508del-CFTR allele in a phase 3, open-label, single-arm study. Objectives: To further evaluate the efficacy and safety of ELX/TEZ/IVA in children 6 through 11 years of age with cystic fibrosis heterozygous for F508del and a minimal function CFTR mutation (F/MF genotypes) in a randomized, double-blind, placebo-controlled phase 3b trial. Methods: Children were randomized to receive either ELX/TEZ/IVA (n = 60) or placebo (n = 61) during a 24-week treatment period. The dose of ELX/TEZ/IVA administered was based on weight at screening, with children <30 kg receiving ELX 100 mg once daily, TEZ 50 mg once daily, and IVA 75 mg every 12 hours, and children ⩾30 kg receiving ELX 200 mg once daily, TEZ 100 mg once daily, and IVA 150 mg every 12 hours (adult dose). Measurements and Main Results: The primary endpoint was absolute change in lung clearance index2.5 from baseline through Week 24. Children given ELX/TEZ/IVA had a mean decrease in lung clearance index2.5 of 2.29 units (95% confidence interval [CI], 1.97-2.60) compared with 0.02 units (95% CI, -0.29 to 0.34) in children given placebo (between-group treatment difference, -2.26 units; 95% CI, -2.71 to -1.81; P < 0.0001). ELX/TEZ/IVA treatment also led to improvements in the secondary endpoint of sweat chloride concentration (between-group treatment difference, -51.2 mmol/L; 95% CI, -55.3 to -47.1) and in the other endpoints of percent predicted FEV1 (between-group treatment difference, 11.0 percentage points; 95% CI, 6.9-15.1) and Cystic Fibrosis Questionnaire-Revised Respiratory domain score (between-group treatment difference, 5.5 points; 95% CI, 1.0-10.0) compared with placebo from baseline through Week 24. The most common adverse events in children receiving ELX/TEZ/IVA were headache and cough (30.0% and 23.3%, respectively); most adverse events were mild or moderate in severity. Conclusions: In this first randomized, controlled study of a cystic fibrosis transmembrane conductance regulator modulator conducted in children 6 through 11 years of age with F/MF genotypes, ELX/TEZ/IVA treatment led to significant improvements in lung function, as well as robust improvements in respiratory symptoms and cystic fibrosis transmembrane conductance regulator function. ELX/TEZ/IVA was generally safe and well tolerated in this pediatric population with no new safety findings. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

21. 6-month multidisciplinary follow-up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS-TS) at a UK tertiary paediatric hospital: a retrospective cohort study

Author

Penner, Justin, primary, Abdel-Mannan, Omar, additional, Grant, Karlie, additional, Maillard, Sue, additional, Kucera, Filip, additional, Hassell, Jane, additional, Eyre, Michael, additional, Berger, Zoe, additional, Hacohen, Yael, additional, Moshal, Karyn, additional, Wyatt, Michelle, additional, Cavalli, Lesley, additional, Mathias, Mary, additional, Bamford, Alasdair, additional, Shingadia, Delane, additional, Alders, Nele, additional, Grandjean, Louis, additional, Gaynor, Edward, additional, Brugha, Rossa, additional, Stojanovic, Jelena, additional, Johnson, Mae, additional, Whittaker, Elizabeth, additional, Pressler, Ronit, additional, and Papadopoulou, Charalampia, additional

Published
2021
Full Text
View/download PDF

22. Carbon in airway macrophages from children with asthma

Author

Brugha, Rossa E, Mushtaq, Naseem, Round, Thomas, Gadhvi, Dev H, Dundas, Isobel, Gaillard, Erol, Koh, Lee, Fleming, Louise J, Lewis, Daniel J, Sanak, Marek, Wood, Helen E, Barratt, Benjamin, Mudway, Ian S, Kelly, Frank J, Griffiths, Christopher J, and Grigg, Jonathan

Published
2014
Full Text
View/download PDF

42. Airway dendritic cell maturation in children exposed to air pollution

Author

Whitehouse, Abigail L., primary, Mushtaq, Naseem, additional, Miyashita, Lisa, additional, Barratt, Benjamin, additional, Khan, Ameerah, additional, Kalsi, Harpal, additional, Koh, Lee, additional, Padovan, Michele G., additional, Brugha, Rossa, additional, Balkwill, Frances R., additional, Stagg, Andrew J., additional, and Grigg, Jonathan, additional

Published
2020
Full Text
View/download PDF

43. Pocket Tutor: Paediatric Clinical Examination

Author

Shiels, Keir, Brugha, Rossa, Shiels, Keir, and Brugha, Rossa

Subjects
Newborn infants, Children--Medical examinations--Handbooks, manuals, etc
Abstract

Pocket Tutor Paediatric Clinical Examination is the perfect companion for medical students, junior doctors and general practitioners seeking an accessible and practical guide to clinical skills in paediatrics.

Published
2019

44. Urinary prostanoids in preschool wheeze

Author

Grigg, Jonathan, primary, Whitehouse, Abigail, additional, Pandya, Hitesh, additional, Turner, Stephen, additional, Griffiths, Christopher J., additional, Vulliamy, Tom, additional, T. Walton, Robert, additional, Price, David B., additional, Sanak, Marek, additional, Holloway, John W., additional, Noimark, Lee, additional, Lesosky, Maia, additional, Brugha, Rossa, additional, Koh, Lee, additional, and Nwokoro, Chinedu, additional

Published
2016
Full Text
View/download PDF

45. Pocket Tutor Paediatric Clinical Examination

Author

Brugha, Rossa, Marlais, Matko, Abrahamson, Ed, Brugha, Rossa, Marlais, Matko, and Abrahamson, Ed

Subjects
Children--Physical examination and diagnosis, Children--Medical examinations, Physical diagnosis
Abstract

The book Pocket Tutor Paediatric Clinical Examination guide paediatricians to deal with problems posed during clinical examination of children. Since each child is different, the book helps one to develop their one style and approach in dealing with paediatrics. The book gives a brief general introduction to history and examination in children. The topics discussed include the respiratory system, the cardiovascular system, the abdomen, the nervous system, the musculoskeletal system, lumps and bumps, skin and rashes, ENT, eyes, and genetic disorders and syndromes. For each system, common presentations and examination are described. This is followed by a couple of case scenarios which demonstrate how they relate to clinical practice.

Published
2013

48. Parent-determined oral montelukast therapy for preschool wheeze with stratification for arachidonate 5-lipoxygenase (ALOX5) promoter genotype: a multicentre, randomised, placebo-controlled trial

Author

Nwokoro, Chinedu, primary, Pandya, Hitesh, additional, Turner, Stephen, additional, Eldridge, Sandra, additional, Griffiths, Christopher J, additional, Vulliamy, Tom, additional, Price, David, additional, Sanak, Marek, additional, Holloway, John W, additional, Brugha, Rossa, additional, Koh, Lee, additional, Dickson, Iain, additional, Rutterford, Clare, additional, and Grigg, Jonathan, additional

Published
2015
Full Text
View/download PDF

50. Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo-controlled trial

Author

Nwokoro, Chinedu, primary, Pandya, Hitesh, additional, Turner, Stephen, additional, Eldridge, Sandra, additional, Griffiths, Christopher J, additional, Vulliamy, Tom, additional, Price, David, additional, Sanak, Marek, additional, Holloway, John W, additional, Brugha, Rossa, additional, Koh, Lee, additional, Dickson, Iain, additional, Rutterford, Clare, additional, and Grigg, Jonathan, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results